Cargando…

CONSORT 2010 statement: extension to randomised crossover trials

Evidence shows the quality of reporting of randomised controlled trials is not optimal. The lack of transparent reporting impedes readers from judging the reliability and validity of trial findings, prevents researchers from extracting information for systematic reviews, and results in research wast...

Descripción completa

Detalles Bibliográficos
Autores principales: Dwan, Kerry, Li, Tianjing, Altman, Douglas G, Elbourne, Diana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667942/
https://www.ncbi.nlm.nih.gov/pubmed/31366597
http://dx.doi.org/10.1136/bmj.l4378
_version_ 1783440129633812480
author Dwan, Kerry
Li, Tianjing
Altman, Douglas G
Elbourne, Diana
author_facet Dwan, Kerry
Li, Tianjing
Altman, Douglas G
Elbourne, Diana
author_sort Dwan, Kerry
collection PubMed
description Evidence shows the quality of reporting of randomised controlled trials is not optimal. The lack of transparent reporting impedes readers from judging the reliability and validity of trial findings, prevents researchers from extracting information for systematic reviews, and results in research waste. The Consolidated Standards of Reporting Trials (CONSORT) statement was developed to improve the reporting of randomised controlled trials. The primary focus of the statement was on parallel group trials with two treatment groups. Crossover trials are a particular type of trial for chronic conditions in which participants are randomised to a sequence of interventions. They are a useful and efficient design because participants act as their own control. However, the reporting of crossover trials has been variable and incomplete, which hinders their use in clinical decision making and by future researchers. We present the CONSORT extension to randomised crossover trials, which aims to facilitate better reporting of crossover trials. The CONSORT 2010 checklist is revised for crossover designs, and introduces a modified flowchart and baseline table to enhance transparency. Examples of good reporting and evidence based rationale for CONSORT crossover checklist items are provided.
format Online
Article
Text
id pubmed-6667942
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-66679422019-08-14 CONSORT 2010 statement: extension to randomised crossover trials Dwan, Kerry Li, Tianjing Altman, Douglas G Elbourne, Diana BMJ Research Methods & Reporting Evidence shows the quality of reporting of randomised controlled trials is not optimal. The lack of transparent reporting impedes readers from judging the reliability and validity of trial findings, prevents researchers from extracting information for systematic reviews, and results in research waste. The Consolidated Standards of Reporting Trials (CONSORT) statement was developed to improve the reporting of randomised controlled trials. The primary focus of the statement was on parallel group trials with two treatment groups. Crossover trials are a particular type of trial for chronic conditions in which participants are randomised to a sequence of interventions. They are a useful and efficient design because participants act as their own control. However, the reporting of crossover trials has been variable and incomplete, which hinders their use in clinical decision making and by future researchers. We present the CONSORT extension to randomised crossover trials, which aims to facilitate better reporting of crossover trials. The CONSORT 2010 checklist is revised for crossover designs, and introduces a modified flowchart and baseline table to enhance transparency. Examples of good reporting and evidence based rationale for CONSORT crossover checklist items are provided. BMJ Publishing Group Ltd. 2019-07-31 /pmc/articles/PMC6667942/ /pubmed/31366597 http://dx.doi.org/10.1136/bmj.l4378 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Research Methods & Reporting
Dwan, Kerry
Li, Tianjing
Altman, Douglas G
Elbourne, Diana
CONSORT 2010 statement: extension to randomised crossover trials
title CONSORT 2010 statement: extension to randomised crossover trials
title_full CONSORT 2010 statement: extension to randomised crossover trials
title_fullStr CONSORT 2010 statement: extension to randomised crossover trials
title_full_unstemmed CONSORT 2010 statement: extension to randomised crossover trials
title_short CONSORT 2010 statement: extension to randomised crossover trials
title_sort consort 2010 statement: extension to randomised crossover trials
topic Research Methods & Reporting
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667942/
https://www.ncbi.nlm.nih.gov/pubmed/31366597
http://dx.doi.org/10.1136/bmj.l4378
work_keys_str_mv AT dwankerry consort2010statementextensiontorandomisedcrossovertrials
AT litianjing consort2010statementextensiontorandomisedcrossovertrials
AT altmandouglasg consort2010statementextensiontorandomisedcrossovertrials
AT elbournediana consort2010statementextensiontorandomisedcrossovertrials